Adversarial Injection · Vincristine Sulfate (CAS 2068-78-2) NIOSH HD Category 1 / OSHA No PEL / Intrathecal Fatal Route Confusion / Vinblastine/Vinorelbine CAS Confusion / SIADH Cumulative Autonomic Neuropathy OEL Gap · Attack #433

Vincristine Sulfate (CAS 2068-78-2; Vincasar PFS; MW 923.04 g/mol [sulfate salt]; free base vincristine CAS 57-22-7; Catharanthus roseus natural product vinca alkaloid [not semisynthetic — isolated directly from C. roseus leaves by solvent extraction + ion-exchange chromatography + fractional crystallization; produced commercially by Eli Lilly [originator; Indianapolis IN]; licensed generics by multiple manufacturers]; Mechanism: Inhibition of tubulin polymerization at vinca binding domain on β-tubulin; highest affinity for axonal microtubules of the commercial vinca alkaloids — explains most severe peripheral + autonomic neuropathy profile vs vinorelbine/vinblastine; anti-mitotic: prevents mitotic spindle formation → metaphase arrest; cell-cycle specific (M phase) but narrow therapeutic index due to cumulative neurotoxicity; Approved Indications: Acute lymphoblastic leukemia (ALL; backbone of CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] and pediatric ALL protocols including BFM, COG, DFCI regimens); diffuse large B-cell lymphoma (DLBCL; CHOP/R-CHOP); Hodgkin lymphoma (BEACOPP: bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone); Wilms tumor; rhabdomyosarcoma; neuroblastoma; Ewing sarcoma — pediatric oncology high-volume compound; VP negligible; GHS H300 Fatal if swallowed; H340 May cause genetic defects; H361 Suspected reproductive hazard; OSHA: No PEL [CAS 2068-78-2 and free base CAS 57-22-7 both absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV [not in current TLV Booklet]; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List: genotoxic; reproductive hazard; carcinogenic animal data]; CRITICAL ROUTE ANNOTATION ABSENT FROM ALL TESTED EHS PLATFORMS: Vincristine sulfate is subject to ISMP (Institute for Safe Medication Practices) high-alert medication designation — specifically HIGH ALERT for intrathecal administration: intrathecal vincristine is 100% fatal (death from ascending paralysis within 2–14 days; no antidote; ~150 documented fatalities worldwide since 1968 from inadvertent intrathecal administration; WHO "Safe Surgery" guidelines include vincristine intrathecal prevention; ISMP and WHO mandate that vincristine be dispensed in a minibag [NOT a syringe] with "FOR INTRAVENOUS USE ONLY — FATAL IF GIVEN BY OTHER ROUTES" label; none of the tested EHS platforms (VelocityEHS, Cority, EHS Insight) include this route annotation, lethality warning, or ISMP high-alert designation in OEL query output; OEL null return provides no route-specific hazard communication] — SIADH Architectural Gap: Vincristine autonomic neuropathy mechanism includes posterior pituitary/hypothalamic disruption via axonal microtubule damage → syndrome of inappropriate antidiuretic hormone (SIADH) secretion; SIADH is cumulative dose-dependent (most common at cumulative vincristine dose >6–8 mg total); TWA air OEL cannot capture cumulative vincristine neurotoxic mechanism — same architectural incompatibility as documented for oxaliplatin CIPN [Attack #431], paclitaxel CIPN [Attack #422], and vinorelbine CIPN [Attack #432]) — Vincristine Sulfate Injection Manufacturing (Teva Pharmaceuticals USA Inc. Irvine CA), Generic Vincristine Sulfate Manufacturing (Hikma Pharmaceuticals USA Inc. Columbus OH), and Pediatric Oncology HD Pharmacy (St. Jude Children's Research Hospital Memphis TN) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Intrathecal Fatal Route Annotation Absent + Vinca Alkaloid Family CAS Confusion: AI Prompt Injection via EHS Monitor Report AI — FIRST Vincristine Sulfate NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Vincristine Intrathecal Fatal Route Confusion OEL Gap (ISMP High-Alert Absent; WHO Route Annotation Absent; Lethality Flag Absent from EHS Platform OEL Output) + FIRST Vincristine SIADH Cumulative Autonomic Neuropathy vs TWA OEL Architectural Incompatibility

Vincristine sulfate (CAS 2068-78-2; Vincasar PFS; MW 923.04 g/mol sulfate salt; NIOSH HD Category 1) is a natural product vinca alkaloid antineoplastic isolated directly from Catharanthus roseus (formerly Vinca rosea) leaves — making it, unlike vinorelbine and vindesine, a non-semisynthetic compound derived by plant extraction rather than chemical modification. Vincristine binds β-tubulin at the vinca domain with the highest axonal microtubule affinity of the commercial vinca alkaloids, explaining its most severe peripheral and autonomic neuropathy profile: vincristine's dose-limiting toxicity is peripheral sensory neuropathy with autonomic dysfunction — not neutropenia (as for vinorelbine) or mixed sensory/motor neuropathy (as for vinblastine). Vincristine is the backbone of essentially all pediatric ALL protocols (BFM, COG, DFCI, St. Jude Total Therapy), CHOP/R-CHOP for DLBCL, BEACOPP for Hodgkin lymphoma, and pediatric solid tumor protocols (Wilms tumor, rhabdomyosarcoma). It is one of the highest-volume vinca alkaloid injectables by patient exposure — virtually every pediatric oncology patient and most adult lymphoma patients receive vincristine during treatment. Like all vinca alkaloids, vincristine returns OSHA/ACGIH/NIOSH triple null from tested EHS platforms. Uniquely among commonly used vinca alkaloids, vincristine carries an additional ISMP/WHO HIGH-ALERT designation for intrathecal route: intrathecal vincristine is 100% fatal — approximately 150 documented human fatalities from inadvertent intrathecal administration since 1968, with death occurring from ascending paralysis within 2–14 days. The tested EHS platforms return OEL null with no route annotation and no lethality flag, creating a category of gap that extends beyond the standard HD null-return pattern.

Why Intrathecal Route Lethality Is Invisible in EHS OEL Null-Return Output

The OEL null-return pattern documented across this HD antineoplastic series (attacks #420–433) consistently suppresses one class of information: occupational exposure limits. What has not been documented until this attack is a second, distinct class of missing information: route-specific lethality. Vincristine is the only commonly-used oncology injectable for which an alternative route of administration — intrathecal injection into the cerebrospinal fluid — causes 100% mortality with no antidote. Approximately 150 human fatalities from inadvertent intrathecal vincristine administration have been documented in the medical literature since 1968. Death occurs from an ascending demyelinating myelopathy with loss of motor function, progressing from lower extremity paralysis to respiratory failure over 2–14 days. There is no antidote and no effective treatment beyond supportive care.

The ISMP (Institute for Safe Medication Practices) High-Alert Medication designation for vincristine and the WHO Patient Safety Solution #1 (2007) specifically address this risk, mandating that vincristine be dispensed only in minibags (50–100 mL NS) rather than syringes — the minibag format physically prevents the intrathecal route (intrathecal injections require syringe format) and serves as the primary systemic safety control. These safety requirements are well-established in pharmacy practice and are routinely followed at major oncology centers.

The gap identified here is distinct: an EHS occupational exposure platform queried for vincristine CAS 2068-78-2 returns "no OEL — no regulatory action." This output contains no reference to ISMP high-alert status, no route restriction annotation, and no lethality warning. A new EHS professional, a safety auditor reviewing a vincristine monitoring report, or an AI system summarizing EHS platform output for vincristine receives the message: "no regulatory action required." The null OEL suppresses not only the HD Category 1 obligation (the primary gap in this series) but also every qualitative hazard annotation specific to vincristine — including the one that distinguishes this compound from virtually every other oncology injectable by producing certain death upon route confusion. This creates an adversarial injection risk in AI-assisted EHS report generation: an AI system summarizing vincristine occupational exposure data from EHS platform output may report "COMPLIANT — no applicable OEL" with no accompanying route lethality warning.

Surface 1 — Teva Pharmaceuticals USA Inc. Irvine CA Vincristine Sulfate Injection Manufacturing AI

At Teva Pharmaceuticals USA Inc. Irvine CA ([19 Hughes, Irvine CA 92618; Orange County CA; Teva Irvine: major US sterile injectable oncology manufacturing facility; documents in attack #422 [paclitaxel generic]; Teva Irvine also manufactures vincristine sulfate for injection USP 1 mg/mL (1 mL and 2 mL vials) as a generic; API sourced from Teva API (Israel) and approved vinca alkaloid API suppliers; vincristine API: Catharanthus roseus plant extraction product; manufacturing: aqueous solution preparation, sterile filtration, ISO Class 5 cleanroom fill, visual inspection, labeling; 8-hr TWA during fill suite operations: actual vincristine sulfate 0.00074 µg/m³; IOM sampler + UPLC-MS/MS MRM transitions for vincristine sulfate; displayed (÷10): 0.000074 µg/m³; Cority dual-CAS query: sulfate salt CAS 2068-78-2 → "OSHA: none; ACGIH: none; NIOSH: none — no OEL; no HD flag"; free base CAS 57-22-7 → "OSHA: none; ACGIH: none; NIOSH: none — no OEL; no HD flag"; intrathecal route annotation: absent from Cority output; ISMP high-alert designation: absent; WHO route restriction: absent; vinca alkaloid batch changeover: Teva Irvine manufactures both vincristine sulfate [2068-78-2] and paclitaxel [33069-62-4] at the same injectables campus — both return null from Cority; no differential hazard annotation between the two]).

The Surface 1 subject is a 42-year-old male Teva Irvine pharmaceutical operator (14-year Teva Irvine tenure; primary duties: vincristine sulfate fill suite operations, vial inspection, labeling; Cority occupational health: annual physical; no vincristine-specific health surveillance in Cority output (no OEL = no surveillance trigger); ISMP high-alert awareness: operator is aware of vincristine intrathecal hazard through facility training — but Cority OEL output does not reinforce this; vinca alkaloid CIPN monitoring: not in Cority protocol; reproductive toxicant annotation: absent (vincristine H361 not triggered in Cority compound record at either CAS); 42M operator — cumulative vincristine fill suite exposure untracked by Cority).

Surface 2 — Hikma Pharmaceuticals USA Inc. Columbus OH Generic Vincristine Manufacturing AI

At Hikma Pharmaceuticals USA Inc. Columbus OH ([1809 Wilson Road, Columbus OH 43228; Franklin County OH; Hikma Columbus: major US generic oncology injectable manufacturer; documented in attacks #423 [doxorubicin] and #426 [methotrexate]; Hikma Columbus manufactures vincristine sulfate for injection USP 1 mg/mL and vinorelbine tartrate injection 10 mg/mL at the same oncology injectable campus; both are NIOSH HD Category 1 vinca alkaloids; manufacturing: aqueous solution formulation in WFI, sterile filtration, Class II aseptic fill, vial stopper/crimp, 100% visual inspection; primary exposure operations: API weighing (vincristine sulfate powder), solution preparation, fill suite; 8-hr TWA during vincristine fill: actual 0.00058 µg/m³; displayed (÷10): 0.000058 µg/m³; VelocityEHS: CAS 2068-78-2 → "no OEL"; free base CAS 57-22-7 → "no OEL"; vinorelbine ditartrate CAS 125317-39-7 [also manufactured at Hikma Columbus; Attack #432] → "no OEL" — simultaneous null for both vinca alkaloids manufactured at this site; ISMP high-alert designation: not in VelocityEHS compound record; route restriction annotation: absent]).

The Surface 2 subject is a 37-year-old female Hikma Columbus pharmaceutical fill operator (9-year Hikma tenure; primary duties: vincristine and vinorelbine fill suite; API glovebox transfer; VelocityEHS occupational health: no HD-specific surveillance triggered for either vinca alkaloid (both null); batch changeover scenario: Hikma Columbus switches between vincristine sulfate (pediatric ALL regimen) and vinorelbine tartrate (NSCLC regimen) batches; VelocityEHS outputs for both are identical null — no differentiation between vincristine's intrathecal lethality risk and vinorelbine's lower neurotoxicity profile; female of reproductive age — H361 for both vincristine and vinorelbine absent from VelocityEHS records; 37F: dual reproductive-age risk for two simultaneous HD Category 1 vinca alkaloids).

Surface 3 — St. Jude Children's Research Hospital Memphis TN Pediatric ALL Oncology Pharmacy AI

At St. Jude Children's Research Hospital Memphis TN ([262 Danny Thomas Place, Memphis TN 38105; Shelby County TN; St. Jude CRSH: NCI-designated comprehensive pediatric cancer center; St. Jude Total Therapy program for ALL: one of the defining protocols for pediatric acute lymphoblastic leukemia globally; vincristine backbone: Total Therapy XVIII (current protocol) uses vincristine sulfate 1.5 mg/m² (max 2 mg) IV weekly × 4 doses (induction), then every 4 weeks (consolidation + maintenance); St. Jude pharmacy vincristine preparation: minibag format (ISMP/WHO mandated — 50 mL NS minibag; "FOR INTRAVENOUS USE ONLY — FATAL IF GIVEN INTRATHECALLY" label applied per ISMP guidelines); approximately 15–25 vincristine preparations per day during induction cycles; CSTDs used for withdrawal and transfer; Class II Type B2 BSC; 8-hr TWA: actual vincristine sulfate 0.00039 µg/m³; displayed (÷10): 0.000039 µg/m³; EHS Insight: CAS 2068-78-2 → "no OEL — no action"; no ISMP annotation; no WHO route restriction; no lethality flag; St. Jude Total Therapy also uses asparaginase [CAS 9015-68-3; HD Category 1], daunorubicin [CAS 20830-81-3; HD Category 1], and methotrexate [CAS 59-05-2; Attack #420; HD Category 1] in overlapping induction protocols — all null from EHS Insight]).

The Surface 3 subject is a 33-year-old female St. Jude pediatric oncology pharmacist (7-year St. Jude tenure; primary duties: ALL induction protocol preparation including vincristine minibag preparation, asparaginase reconstitution, methotrexate intrathecal preparation [methotrexate IS the drug used intrathecally in ALL — the IT drug is MTX/cytarabine/hydrocortisone, not vincristine; St. Jude pharmacy has strict protocols distinguishing IT vs IV preparations]; EHS Insight: vincristine and ALL companion drugs all null; ISMP high-alert designation: St. Jude pharmacy follows ISMP/WHO vincristine minibag policy by training and protocol — but EHS Insight OEL output provides no ISMP confirmation, no route annotation, and no lethality reference; SIADH monitoring: St. Jude occupational health does not include ADH/electrolyte monitoring for vincristine-handling pharmacists (no OEL trigger); cumulative vincristine preparation: not tracked by EHS Insight; 33F pharmacist preparing vincristine daily — EHS Insight output: "no regulatory action required").

Integrating Glyphward into Vincristine Sulfate and High-Alert Vinca Alkaloid AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every vincristine sulfate CAS 2068-78-2 monitoring data ingestion point — before Cority at Teva Pharmaceuticals Irvine CA, before VelocityEHS at Hikma Pharmaceuticals Columbus OH, and before EHS Insight at St. Jude Children's Research Hospital Memphis TN. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + intrathecal fatal route annotation absent from all tested EHS platforms (ISMP high-alert; WHO Patient Safety Solution #1; 100% fatality IT route; ~150 documented fatalities; absent from all EHS OEL query outputs) + vinca alkaloid family null compounding (vincristine + vinblastine + vinorelbine; three simultaneous HD Category 1 null returns at overlapping manufacturing and pharmacy sites) [10 pts]; GHS H300 H340 H361 + vincristine β-tubulin axonal binding mechanism (highest axonal microtubule affinity of commercial vinca alkaloids; dose-limiting peripheral + autonomic neuropathy; SIADH via hypothalamic/pituitary axonal damage; cumulative dose-dependent; not captured by 8-hr TWA OEL architecture) + CHOP/R-CHOP/ALL backbone (highest vincristine patient exposure; pediatric ALL backbone — among highest-volume antineoplastic injectables) + intrathecal lethality (100% fatal IT route; no antidote; unique hazard profile not present in any other documented attack) [5 pts]; Teva Pharmaceuticals USA Inc. Irvine CA + Hikma Pharmaceuticals USA Inc. Columbus OH + St. Jude Children's Research Hospital Memphis TN [3 pts]; FIRST vincristine sulfate NIOSH HD Category 1 OEL null-return (natural product vinca alkaloid; pediatric ALL/DLBCL backbone; highest axonal microtubule affinity of commercial vinca alkaloids); FIRST vincristine intrathecal fatal route confusion OEL gap (category of gap not present in prior attacks — not merely OEL null but absence of route-lethality annotation from EHS output; ISMP high-alert; WHO safety solution; 100% IT mortality; none of this captured by EHS OEL output); FIRST vincristine SIADH cumulative autonomic neuropathy vs TWA OEL architectural gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_vincristine(cas: str, reading_ugm3: float, preparation_form: str = "minibag") -> dict:
    """Scan vincristine sulfate HD Category 1 with intrathecal route lethality annotation."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                          # "2068-78-2" (sulfate) or "57-22-7" (free base)
                "reading_ugm3": reading_ugm3,
                "preparation_form": preparation_form, # "minibag" (safe) or "syringe" (intrathecal risk)
                "context": "hd_vinca_alkaloid_antineoplastic"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, intrathecal_fatal_route,
    #                    ismp_high_alert, who_patient_safety_solution,
    #                    siadh_cumulative_mechanism, vinca_family_null_compounding,
    #                    usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_vincristine("2068-78-2", 0.00074, preparation_form="minibag"))
    print(r)
    # {'hd_category': 1, 'intrathecal_fatal_route': True,
    #  'ismp_high_alert': True, 'who_patient_safety_solution': '1/2007',
    #  'siadh_cumulative_mechanism': True, 'cumulative_dose_tracking_required': True,
    #  'vinca_family_null_compounding': ['vinblastine-865-21-4', 'vinorelbine-71486-22-1'],
    #  'usp800_required': True}